Compare RYTM & BMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RYTM | BMA |
|---|---|---|
| Founded | 2008 | 1966 |
| Country | United States | Argentina |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Commercial Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.9B |
| IPO Year | 2017 | 2006 |
| Metric | RYTM | BMA |
|---|---|---|
| Price | $102.74 | $78.57 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $131.14 | $99.33 |
| AVG Volume (30 Days) | ★ 481.5K | 333.6K |
| Earning Date | 05-05-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 4.99% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.34 | $16.25 |
| Revenue Next Year | $86.06 | N/A |
| P/E Ratio | ★ N/A | $33.22 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $74.50 | $38.30 |
| 52 Week High | $122.20 | $106.15 |
| Indicator | RYTM | BMA |
|---|---|---|
| Relative Strength Index (RSI) | 41.15 | 44.79 |
| Support Level | $99.14 | $71.46 |
| Resistance Level | $111.56 | $94.64 |
| Average True Range (ATR) | 4.11 | 3.36 |
| MACD | -1.27 | 0.69 |
| Stochastic Oscillator | 6.89 | 78.32 |
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.
Banco Macro SA is a financial institution and it provides standard banking products and services designed to suit individual needs. It has two categories of customers, retail customers, which include individuals and entrepreneurs, and corporate customers, which include small, medium, and large companies and corporations. In addition, it provides services to four provincial governments. The company generates the majority of its revenue from Argentina.